Cytokinetics, Inc. (CYTK) Reports In-Line Q2 Loss of 13c/Share
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $69.39 --0%
Revenue Growth %: +1,966.3%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: +1,966.3%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13).
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- The Fed is hiking. Why isn't UBS worried about stocks?
- S&P Global agrees to acquire blockchain security firm OpenZeppelin
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
